• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

探讨日本人及亚洲人群狼疮性肾炎的临床病理特征。

Clinicopathological insights into lupus glomerulonephritis in Japanese and Asians.

机构信息

Division of Nephrology, Kanazawa Medical University School of Medicine, Uchinada, Japan.

出版信息

Clin Exp Nephrol. 2011 Jun;15(3):321-330. doi: 10.1007/s10157-011-0434-0. Epub 2011 Mar 25.

DOI:10.1007/s10157-011-0434-0
PMID:21437578
Abstract

Lupus nephritis comprises a spectrum of glomerular, vascular, and tubulointerstitial lesions, which has significant racial variation in severity and manifestations. The current classification (ISN/RPS 2003) has been improved successfully for the categorization of lupus glomerulonephritis (LGN). On the basis of this classification, 480 Japanese cases revealed the following distribution: class I 3%, class II 16%, class III 13%, class IV-S 11%, class IV-G 41%, class V 16%, and class VI 1%. Class IV-G with chronicity tended to have the worst renal outcome. Nephrotic syndrome was a more frequent complication in class IV-S (50%), class IV-G (72%), and class V (56%), with poor renal and actuarial outcomes. With regard to therapy, treatment options including glucocorticoids alone or combined with antimetabolites (azathioprine, mizoribine, mycophenolate mofetil), calcineurin inhibitors (cyclosporine A, tacrolimus), or alkylating agents (intravenous cyclophosphamide injection) improved the outcome of LGN; however, there is no high-grade clinical evidence from Japan. Further studies are needed to resolve the clinicopathological problems of LGN, especially IV-S, IV-G, and pure membranous lupus nephritis in Japanese patients.

摘要

狼疮肾炎包括一系列肾小球、血管和小管间质病变,其严重程度和表现具有显著的种族差异。目前的分类(ISN/RPS 2003)已经成功地改进了狼疮性肾小球肾炎(LGN)的分类。基于这一分类,480 例日本病例的分布如下:I 型 3%,II 型 16%,III 型 13%,IV-S 型 11%,IV-G 型 41%,V 型 16%,VI 型 1%。慢性 IV-G 型倾向于有最差的肾脏结局。肾病综合征在 IV-S(50%)、IV-G(72%)和 V 型(56%)中更为常见,肾脏和实际结局较差。关于治疗,包括糖皮质激素单独或联合抗代谢药物(硫唑嘌呤、霉酚酸酯、来氟米特)、钙调神经磷酸酶抑制剂(环孢素 A、他克莫司)或烷化剂(环磷酰胺静脉注射)在内的治疗选择改善了 LGN 的结局;然而,日本没有来自高级别临床证据。需要进一步的研究来解决 LGN 的临床病理问题,特别是在日本患者中 IV-S、IV-G 和纯膜性狼疮肾炎。

相似文献

1
Clinicopathological insights into lupus glomerulonephritis in Japanese and Asians.探讨日本人及亚洲人群狼疮性肾炎的临床病理特征。
Clin Exp Nephrol. 2011 Jun;15(3):321-330. doi: 10.1007/s10157-011-0434-0. Epub 2011 Mar 25.
2
The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese.日本狼疮性肾炎的结局及国际肾脏病学会/肾脏病理学会2003年新分类
Kidney Int. 2004 Dec;66(6):2382-8. doi: 10.1111/j.1523-1755.2004.66027.x.
3
The difference between lupus nephritis class IV-G and IV-S in Koreans: focus on the response to cyclophosphamide induction treatment.韩国狼疮性肾炎IV-G型和IV-S型的差异:聚焦于环磷酰胺诱导治疗的反应
Rheumatology (Oxford). 2008 Mar;47(3):311-4. doi: 10.1093/rheumatology/kem365. Epub 2008 Jan 19.
4
The prognosis and pathogenesis of severe lupus glomerulonephritis.重症狼疮性肾炎的预后与发病机制。
Nephrol Dial Transplant. 2008 Apr;23(4):1298-306. doi: 10.1093/ndt/gfm775. Epub 2007 Nov 28.
5
The classification of glomerulonephritis in systemic lupus erythematosus revisited.系统性红斑狼疮中肾小球肾炎的分类再探讨。
Kidney Int. 2004 Feb;65(2):521-30. doi: 10.1111/j.1523-1755.2004.00443.x.
6
Immunosuppressive treatment for proliferative lupus nephritis.增殖性狼疮性肾炎的免疫抑制治疗
Cochrane Database Syst Rev. 2018 Jun 29;6(6):CD002922. doi: 10.1002/14651858.CD002922.pub4.
7
Efficacy and safety of multitarget therapy with cyclophosphamide and tacrolimus for lupus nephritis: a prospective, single-arm, single-centre, open label pilot study in Japan.环磷酰胺和他克莫司多靶点疗法治疗狼疮性肾炎的疗效与安全性:日本一项前瞻性、单臂、单中心、开放标签的试点研究
Lupus. 2018 Feb;27(2):273-282. doi: 10.1177/0961203317719148. Epub 2017 Jul 6.
8
Classification of lupus nephritis.狼疮性肾炎的分类
Curr Opin Nephrol Hypertens. 2009 May;18(3):220-5. doi: 10.1097/mnh.0b013e328327b379.
9
The value of early renal biopsy in systemic lupus erythematosus patients presenting with renal involvement.早期肾活检在出现肾脏受累的系统性红斑狼疮患者中的价值。
Clin Nephrol. 2012 Jan;77(1):18-24. doi: 10.5414/cn107094.
10
New subcategories of class IV lupus nephritis: are there clinical, histologic, and outcome differences?IV 型狼疮性肾炎的新亚类:是否存在临床、组织学及预后差异?
Am J Kidney Dis. 2004 Dec;44(6):1050-9. doi: 10.1053/j.ajkd.2004.08.027.

引用本文的文献

1
Treatment Outcomes of Proliferative vs. Non-proliferative Adult Lupus Nephritis: A 10-Year Follow-Up.增殖性与非增殖性成人狼疮性肾炎的治疗结果:10年随访
Cureus. 2021 Aug 6;13(8):e16955. doi: 10.7759/cureus.16955. eCollection 2021 Aug.
2
Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis.狼疮性肾炎联合临床试验中肾病综合征参与者的结局
Lupus Sci Med. 2019 Feb 4;6(1):e000308. doi: 10.1136/lupus-2018-000308. eCollection 2019.
3
Long-term Outcome of Lupus Nephritis Class II in Argentine Patients: An Open Retrospective Analysis.

本文引用的文献

1
[New insight into nephrotic lupus glomerulonephritis].[狼疮性肾炎肾病综合征的新见解]
Nihon Jinzo Gakkai Shi. 2010;52(7):903-7.
2
Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.利妥昔单抗治疗系统性红斑狼疮的安全性和有效性:来自法国自身免疫与利妥昔单抗注册研究的136例患者的结果
Arthritis Rheum. 2010 Aug;62(8):2458-66. doi: 10.1002/art.27541.
3
The long-term prognosis of lupus nephritis patients treated with intravenous cyclophosphamide.接受静脉注射环磷酰胺治疗的狼疮性肾炎患者的长期预后。
阿根廷患者狼疮性肾炎II级的长期预后:一项开放性回顾性分析
J Clin Rheumatol. 2016 Sep;22(6):299-306. doi: 10.1097/RHU.0000000000000395.
4
Clinical features and mortality in Chinese with lupus nephritis and neuropsychiatric lupus: A 124-patient study.中国狼疮性肾炎和神经精神性狼疮患者的临床特征与死亡率:一项纳入124例患者的研究
J Res Med Sci. 2014 May;19(5):414-9.
5
Membranous nephropathy in Japan: analysis of the Japan Renal Biopsy Registry (J-RBR).日本的膜性肾病:日本肾活检注册研究(J-RBR)分析。
Clin Exp Nephrol. 2012 Aug;16(4):557-63. doi: 10.1007/s10157-012-0593-7. Epub 2012 Feb 23.
6
Recent advances in the treatment of lupus nephritis.狼疮肾炎治疗的新进展。
Clin Exp Nephrol. 2012 Apr;16(2):202-13. doi: 10.1007/s10157-011-0556-4. Epub 2011 Nov 8.
Intern Med. 2010;49(9):823-8. doi: 10.2169/internalmedicine.49.2291. Epub 2010 Apr 30.
4
Tacrolimus is effective for lupus nephritis patients with persistent proteinuria.他克莫司对持续性蛋白尿的狼疮肾炎患者有效。
Clin Exp Rheumatol. 2010 Jan-Feb;28(1):6-12.
5
Inflammation: Rituximab in ANCA vasculitis and lupus: bittersweet results.炎症:利妥昔单抗治疗抗中性粒细胞胞浆抗体相关性血管炎和狼疮:喜忧参半的结果。
Nat Rev Nephrol. 2010 Mar;6(3):137-9. doi: 10.1038/nrneph.2010.13.
6
Improvement of rapidly progressive lupus nephritis associated MPO-ANCA with tacrolimus.他克莫司改善快速进展性狼疮肾炎相关 MPO-ANCA。
Mod Rheumatol. 2010 Jun;20(3):291-4. doi: 10.1007/s10165-009-0266-x. Epub 2010 Jan 15.
7
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.利妥昔单抗治疗中度至重度活动性系统性红斑狼疮的疗效和安全性:利妥昔单抗治疗系统性红斑狼疮的随机、双盲、II/III期试验
Arthritis Rheum. 2010 Jan;62(1):222-33. doi: 10.1002/art.27233.
8
An overview of regular dialysis treatment in Japan (as of 31 December 2007).日本常规透析治疗概况(截至2007年12月31日)。
Ther Apher Dial. 2009 Dec;13(6):457-504. doi: 10.1111/j.1744-9987.2009.00789.x.
9
Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study.种族/民族对狼疮肾炎治疗反应的影响:ALMS 研究。
Rheumatology (Oxford). 2010 Jan;49(1):128-40. doi: 10.1093/rheumatology/kep346. Epub 2009 Nov 20.
10
Combination therapy with steroids and mizoribine in juvenile SLE: a randomized controlled trial.联合应用激素和吗替麦考酚酯治疗幼年特发性关节炎:一项随机对照试验
Pediatr Nephrol. 2010 May;25(5):877-82. doi: 10.1007/s00467-009-1341-4. Epub 2009 Nov 10.